We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+7.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$357M
AUM Growth
+$14.3M
Cap. Flow
-$378K
Cap. Flow %
-0.11%
Top 10 Hldgs %
60.48%
Holding
73
New
21
Increased
19
Reduced
16
Closed
11
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
0.7 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
ENSG icon
The Ensign Group
ENSG
+$7.79M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.69M
3
BOLD icon
Audentes Therapeutics, Inc
BOLD
+$6.13M
4
ILMN icon
Illumina
ILMN
+$5.94M
5
CNC icon
Centene
CNC
+$4.1M

Top Sells

Rank Stock Value
1
NUVA
NuVasive, Inc.
NUVA
+$14.1M
2
AMRN icon
Amarin Corp
AMRN
+$9.2M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.15M
4
ABMD
Abiomed Inc
ABMD
+$7.81M
5
AERI
Aerie Pharmaceuticals
AERI
+$5.45M

Sector Composition

Rank Sector Weight
1 Healthcare 82.49%
2 Industrials 9.51%
3 Financials 4.31%
4 Miscellaneous 1.99%
5 Real Estate 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RCM icon
1
DELISTED
R1 RCM Inc. Common Stock
RCM
$34M 9.51%
2,699,159
-264,500
-9% -$2.99M
2017 Q4
6 quarters
AMRN icon
2
Amarin Corp
AMRN
$244M
$30.2M 8.46%
77,903
-25,111
-24% -$9.2M
2018 Q1
5 quarters
GSK icon
3
GSK
GSK
$99.5B
$28.1M 7.87%
554,948
-87,600
-14% -$4.4M
2018 Q1
5 quarters
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$25.6M 7.18%
536,794
+41,365
+8% +$1.67M
2017 Q4
6 quarters
DHR icon
5
Danaher
DHR
$162B
$20.8M 5.81%
163,677
-15,409
-9% -$1.82M
2018 Q3
3 quarters
ENSG icon
6
The Ensign Group
ENSG
$10.4B
$17.4M 4.87%
326,561
+156,007
+91% +$7.79M
2017 Q4
6 quarters
RDUS icon
7
DELISTED
Radius Health, Inc.
RDUS
$17.3M 4.85%
710,517
+65,100
+10% +$1.42M
2017 Q4
6 quarters
ASND icon
8
Ascendis Pharma A/S
ASND
$14.9B
$15.7M 4.4%
136,397
+33,101
+32% +$3.96M
2017 Q4
6 quarters
EHTH icon
9
eHealth
EHTH
$19M
$15.4M 4.31%
178,739
-21,910
-11% -$1.47M
2019 Q1
1 quarter
SNY icon
10
Sanofi
SNY
$96.8B
$11.5M 3.22%
266,062
-66,340
-20% -$2.82M
2017 Q4
6 quarters
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$128B
$10.6M 2.97%
57,849
+19,620
+51% +$3.43M
2017 Q4
6 quarters
TGTX icon
12
TG Therapeutics
TGTX
$8.33B
$7.64M 2.14%
883,501
+134,907
+18% +$1.02M
2018 Q1
5 quarters
DCPH icon
13
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$6.88M 1.93%
305,233
+54,801
+22% +$1.28M
2018 Q4
2 quarters
ARGX icon
14
argenx
ARGX
$51.5B
$6.83M 1.91%
48,264
+8,930
+23% +$1.13M
2017 Q4
6 quarters
ILMN icon
15
Illumina
ILMN
$39.5B
$6.73M 1.89%
+18,802
New +$5.94M
2019 Q2
0 quarters
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$31.5B
$6.32M 1.77%
+87,140
New +$6.69M
2019 Q2
0 quarters
BOLD icon
17
DELISTED
Audentes Therapeutics, Inc
BOLD
$6.04M 1.69%
+159,526
New +$6.13M
2019 Q2
0 quarters
NUVA
18
DELISTED
NuVasive, Inc.
NUVA
$5.37M 1.5%
91,798
-238,803
-72% -$14.1M
2019 Q1
1 quarter
CNC icon
19
Centene
CNC
$34.5B
$5.22M 1.46%
99,600
+76,000
+322% +$4.1M
2018 Q1
5 quarters
ZGNX
20
CALL
DELISTED
Zogenix, Inc.
ZGNX
$4.98M 1.4%
+104,300
New +$4.2M
2019 Q2
0 quarters
ARQL
21
DELISTED
Arqule Inc
ARQL
$4.97M 1.39%
451,688
-195,230
-30% -$1.36M
2018 Q2
4 quarters
FATE icon
22
Fate Therapeutics
FATE
$225M
$4.42M 1.24%
217,856
-132,155
-38% -$2.38M
2018 Q4
2 quarters
ARNA
23
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.31M 1.21%
73,501
-2,220
-3% -$115K
2018 Q1
5 quarters
DERM icon
24
DELISTED
Dermira, Inc.
DERM
$3.82M 1.07%
399,874
+220,374
+123% +$2.37M
2019 Q1
1 quarter
TCDA
25
DELISTED
Tricida, Inc. Common Stock
TCDA
$3.46M 0.97%
87,568
+38,060
+77% +$1.34M
2018 Q3
3 quarters
1
2 3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q2 2019 Portfolio in Review

As of Q2 2019, Eversept Partners held 73 positions worth $357M, up 4.2% from $343M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Eversept Partners's Q2 2019 filing shows 21 new, 19 increased, 16 reduced and 11 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 87,140 shares worth $6.32M. The largest sale was NuVasive, Inc., an estimated $14.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier, followed by Industrials and Financials.

  • Eversept Partners's largest Q2 2019 buy was Alnylam Pharmaceuticals: 87,140 shares worth $6.32M.
  • Eversept Partners added most to The Ensign Group in Q2 2019, an estimated $7.79M increase.
  • Eversept Partners's biggest Q2 2019 reduction was NuVasive, Inc., cutting an estimated $14.1M.
  • Eversept Partners fully exited Abiomed Inc in Q2 2019, selling an estimated $7.81M.
  • Eversept Partners's ten largest holdings make up 60% of its $357M portfolio in Q2 2019.
  • Eversept Partners opened 21 new positions and closed 11 in Q2 2019.
  • Eversept Partners's portfolio value rose 4.2% quarter-over-quarter to $357M.

Based on Eversept Partners's 13F filing for Q2 2019, filed 13 Aug 2019.